JMS Co

JMS Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of JMS Co (7702.T) as of Nov 2, 2026 is 0.29. In the previous year, Long-Term Debt to Equity Ratio was 0.29 — a change of -0.39% (lower).

LT Debt/Equity

0.29

YoY

-0.39%

Last updated:

Long-Term Debt to Equity Ratio of JMS Co is 2026 0.29 . Long-Term Debt to Equity Ratio of JMS Co was 2025 0.29 . It decreases by -0.39% lower compared to the previous year.

The JMS Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2019
0.33 JPY
Jan 1, 2020
0.31 JPY
Jan 1, 2021
0.28 JPY
Jan 1, 2022
0.28 JPY
Jan 1, 2023
0.30 JPY
Jan 1, 2024
0.27 JPY
Jan 1, 2025
0.29 JPY
Jan 1, 2026
0.29 JPY
The JMS Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.29-0.39%
0.29+5.87%
0.27-9.85%
0.30+7.90%
0.28-0.62%
0.28-8.63%
0.31-7.69%
0.33-12.11%
0.38+1.09%
0.38+10.85%
0.34+67.40%
0.20+135.31%
0.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Long-Term Debt to Equity Ratio of JMS Co is 0.29 in 2026.

Long-Term Debt to Equity Ratio of JMS Co changed from 0.29 to 0.29, representing a -0.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio JMS Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's JMS Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — JMS Co

All Key Metrics — JMS Co